Neuroendocrine Tumor Imaging: Which Test When
Choosing among ⁶⁸Ga-DOTATATE, FDG, ¹²³I-MIBG, and ¹⁸F-FDOPA across neuroendocrine phenotypes
Quick Answer
Neuroendocrine tumor (NET) imaging is chosen by tumor differentiation and receptor biology. Well-differentiated, somatostatin-receptor (SSTR)-expressing NETs are best imaged with ⁶⁸Ga-DOTATATE (SSTR PET/CT), which is both the staging test and the gate to peptide receptor radionuclide therapy (PRRT). As tumors dedifferentiate, SSTR expression falls and glucose metabolism rises, so FDG becomes informative and prognostic. ¹²³I-MIBG and ¹⁸F-FDOPA occupy specific niches (catecholamine-secreting tumors, MIBG-therapy planning, medullary thyroid cancer, and some paragangliomas). The unifying concept is the SSTR/FDG "flip-flop": high SSTR/low FDG is favorable and treatable with PRRT; low SSTR/high FDG signals aggressive disease.
The decision in one place
For most well-differentiated GEP-NETs, ⁶⁸Ga-DOTATATE PET/CT is first-line — it stages disease and determines PRRT eligibility. Add FDG when grade is intermediate/high, when clinical behavior outpaces the SSTR scan, or to prognosticate and detect SSTR-negative, FDG-avid disease that PRRT will miss. Reserve MIBG and FDOPA for catecholamine-related and lineage-specific questions.
Head-to-head
| Tracer | Target / biology | Best for | Weakness |
|---|---|---|---|
| ⁶⁸Ga-DOTATATE (SSTR PET) | Somatostatin receptor 2 | Well-differentiated NET staging; PRRT eligibility; small/nodal/bone disease | Falls with dedifferentiation; physiologic uncinate/spleen/adrenal uptake |
| FDG | Glucose metabolism | Higher-grade NET; prognosis; SSTR-negative aggressive disease | Low sensitivity for indolent, well-differentiated tumors |
| ¹²³I-MIBG | Norepinephrine transporter | Pheochromocytoma/paraganglioma; planning ¹³¹I-MIBG therapy; neuroblastoma | Lower sensitivity than DOTATATE for many PPGL; many drug interferences |
| ¹⁸F-FDOPA | AADC / catecholamine pathway | Medullary thyroid cancer, some PPGL, congenital hyperinsulinism, well-diff NET | Availability; variable by tumor type |
How to sequence
By clinical scenario:
- Well-differentiated GEP-NET (G1–G2): ⁶⁸Ga-DOTATATE PET/CT first — for staging and to confirm SSTR expression before PRRT.
- Grade 3 / poorly differentiated, or clinical–imaging discordance: add FDG. Dual SSTR + FDG imaging defines the favorable (SSTR+/FDG−) versus aggressive (SSTR−/FDG+) phenotype and refines whether PRRT alone is adequate.
- Pheochromocytoma/paraganglioma: ⁶⁸Ga-DOTATATE is generally most sensitive (especially head-and-neck and SDHx-related); use MIBG when ¹³¹I-MIBG therapy is contemplated (need to confirm uptake) and FDG in SDHB-related metastatic disease.
- Medullary thyroid cancer: FDOPA and DOTATATE both localize recurrence; yield rises with higher calcitonin.
The flip-flop concept
The SSTR/FDG flip-flop is the organizing idea across NET imaging: as a tumor loses differentiation, SSTR expression decreases while FDG uptake increases. A lesion that is DOTATATE-bright and FDG-negative is favorable and PRRT-treatable; one that is DOTATATE-dim and FDG-avid is aggressive and, like target-negative disease in any theranostic pair, will not be treated by the receptor-targeted therapy — the same logic that governs PSMA/FDG discordance in prostate cancer.
Pitfalls in selection
- Somatostatin analog timing: long-acting SSA can compete with DOTATATE uptake; scheduling the scan relative to the SSA dose matters, though routine SSA withholding is debated.
- Physiologic DOTATATE uptake (uncinate process, spleen/accessory spleen, adrenals, pituitary) mimics disease.
- MIBG interferences: many drugs (labetalol, tricyclics, sympathomimetics) reduce uptake and must be reviewed before imaging or therapy planning.
Bottom line
Start with ⁶⁸Ga-DOTATATE for well-differentiated NET staging and PRRT selection; add FDG for grade, prognosis, and detection of aggressive SSTR-negative disease; use MIBG/FDOPA for catecholamine-related and lineage-specific questions.
Self-Check
Q1. What is the first-line test for a well-differentiated GEP-NET, and why?
Answer: ⁶⁸Ga-DOTATATE (SSTR PET/CT) — it stages the disease and determines PRRT eligibility by confirming somatostatin-receptor expression.
Q2. When should FDG be added, and what does it tell you?
Answer: For intermediate/high grade or clinical–imaging discordance. FDG is prognostic and detects SSTR-negative, FDG-avid aggressive disease that PRRT will not treat.
Q3. Explain the SSTR/FDG flip-flop.
Answer: As a NET dedifferentiates, SSTR expression falls while FDG uptake rises. DOTATATE-bright/FDG-negative is favorable and PRRT-treatable; DOTATATE-dim/FDG-avid is aggressive and receptor-therapy-refractory.
Q4. In which situation is ¹²³I-MIBG specifically indicated over DOTATATE?
Answer: When ¹³¹I-MIBG therapy is being planned — MIBG uptake must be confirmed to establish the target — even though DOTATATE is often more sensitive for detection in PPGL.
Key References
- SNMMI/EANM guidelines for SSTR PET, MIBG, and FDOPA imaging of neuroendocrine tumors.
- Cohorts on dual SSTR/FDG imaging, the NETPET grade, and genotype-driven PPGL imaging (DOTATATE vs MIBG vs FDG).
Evidence & sources
https://nuc.med/neuroendocrine-imaging-selection/ Report an issue